Tuesday, December 9, 2008

"The industry wants a temporary change in tax laws that would allow companies to receive a rebate upfront"

There does seem to be no end to this tune. I don't see a paucity of supplicants for some stimulus money or tax breaks:

"By David Olmos

Dec. 10 (Bloomberg) -- U.S. biotechnology executives are lobbying Congress to change a tax law and provide millions of dollars in government money to small, cash-starved drugmakers that comprise most of the industry.

The industry wants a temporary change in tax laws that would allow companies to receive a rebate upfront in exchange for giving up a portion of net operating losses deductions they are eligible to take once they begin to make a profit, Matt Gardner, president and chief executive of BayBio, an industry group in South San Francisco, California, said yesterday in a telephone interview.

Although its troubles are not as high profile as those of carmakers and banks, the biotechnology industry is facing one of its worst cash shortages in years. The crisis is being felt most severely by smaller companies, which require big infusions of money for costly drug research though they often have no sales. New drugs require hundreds of millions of dollars and more than a decade to develop.

“Most of these companies have not yet had their first product approved” by regulators, said Gardner. “They don’t have any revenue, and they are accumulating these operating losses. This change would allow them to convert some of these losses back into future research spending, which is a very good thing for the economy.”

The effort in Congress is being led by the Biotechnology Industry Organization, or BIO, a Washington, D.C.-based trade group. According to the group’s figures, 25 percent of the 370 publicly traded U.S. biotechnology companies have less than six months of cash on hand. The industry also has been hit by hundreds of layoffs and some bankruptcies.

Under the proposal, a company with $100 million in net operating losses would be entitled to $35 million in lower federal taxes when it becomes profitable, Alan Eisenberg, executive vice president of BIO, told the New York Times. Such a company might receive $20 million now under the proposal, he said.

Gardner said executives from the lobbying group and biotechnology companies would be talking today with lawmakers on Capitol Hill seeking the change."

I'm for it. I just believe in developing new drugs, and I don't mind targeted tax breaks in a downturn to keep

No comments: